Co-Authors
This is a "connection" page, showing publications co-authored by ALESSANDRA FERRAJOLI and MEGAN WANG.
Connection Strength
0.175
-
Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE. Blood. 2024 Sep 24.
Score: 0.062
-
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncol. 2024 Apr; 20(12):717-726.
Score: 0.059
-
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2023 01 26; 388(4):319-332.
Score: 0.055